MedTrace Logo

Epigenetic Tools as Prognostic Predictors in Covid19

NCT04411563 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 105

Last updated 2020-06-02

No results posted yet for this study

Summary

The necessity for early detection and hence improving the outcome of treatment of pneumonia is critical especially SARS-CoV-2 induced cases. This work was designed to evaluate the potential application of measuring circulating epigenetic markers namely, miR-744, miR-24, miR-124, miR-155, miR-19a, miR-122, miR-21, miR-223, let-7f, miR-146, miR-196, miR-136, P13-K, miR-9 expression, and DNA methylation profiling of the ACE2, TMPRSS2, PARP, HOX1 genes in Coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 with/without pneumonia and severe acute respiratory syndrome (SARS) patients as an attempt to evaluate the potential benefits of these new circulating, prognostic, epigenetic markers for Turkish patients.

Conditions

  • Prognosis

Interventions

OTHER

Taking biological samples

Taking blood samples for biochemical and epigenetic analysis

Sponsors & Collaborators

  • Istanbul University

    collaborator OTHER

  • Bakirkoy Dr. Sadi Konuk Research and Training Hospital

    lead OTHER_GOV

Principal Investigators

  • Gokhan T. Adas, Prof · Bakirkoy Dr. Sadi Konuk Research and Training Hospital

  • Asuman Gedikbasi, Assoc.Prof. · Bakirkoy Dr. Sadi Konuk Research and Training Hospital

  • Kadriye Yaşar, Prof. · Bakirkoy Dr. Sadi Konuk Research and Training Hospital

  • Nilgün Isiksacan, Assoc.Prof. · Bakirkoy Dr. Sadi Konuk Research and Training Hospital

  • Zafer Çukurova, Assoc.Prof. · Bakirkoy Dr. Sadi Konuk Research and Training Hospital

  • Oya G. Hergünsel, MD, Intensivist · Bakirkoy Dr. Sadi Konuk Research and Training Hospital

  • Sacide Pehlivan, Prof. · Istanbul University

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-21
Primary Completion
2020-09-30
Completion
2020-12-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04411563 on ClinicalTrials.gov